Last reviewed · How we verify
Longeveron Mesenchymal Stem Cells
At a glance
| Generic name | Longeveron Mesenchymal Stem Cells |
|---|---|
| Also known as | LMSCs |
| Sponsor | Longeveron Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER) (PHASE1)
- Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) (PHASE1, PHASE2)
- Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty (PHASE1, PHASE2)
- Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty (PHASE2)
- Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Longeveron Mesenchymal Stem Cells CI brief — competitive landscape report
- Longeveron Mesenchymal Stem Cells updates RSS · CI watch RSS
- Longeveron Inc. portfolio CI